Some survey articles exist, one of which is Stephen Olmstead’s monograph from 1998 which showed predominantly positive evidence and suggested the need for further scientific research. It was never published, but can be found as a manuscript.
In 1993 Chappell and Stahl published a so-called Meta analysis which showed an improvement in 88% of patients and a clear improvement in cardiovascular disease.
The studies which have been made in the public sector have had poor statistical strength, have been undertaken by competing occupations (vascular surgeons), and have had major scientific flaws (design, statistics, dropout, blinding, mixing, lack of placebo, protocol failure, and so on).
All of these groups have concluded that ETDA chelation has no effect, which was in all of the studies contrary to their own data.
In the United States 30 million dollars has been approved for use for a large placebo controlled trial involving 2,400 cardiac patients for a period of five years. All of the patients in this study will undergo 40 treatments, the results of which will be interpreted by independent researchers. Unfortunately this study has met massive obstruction from cardiologists in the United States, which means that patient recruitment has been extremely slow.
We are a group of doctors form the United States, Denmark, Holland, and Brazil who, because of the preceding, conducted a study one year ago. We used the precisely the same statistical methodology for our cardiac patients as had earlier been used in evaluations of by pass operations, balloon dilatations, and medicinal treatment for comparison of these treatments. Also, the patients who took part in our study were completely comparable to those in the aforementioned studies in terms of surgical indication and illness severity.
We used so-called “hard end points” like death and blood clots in the heart and brain as primary measurement parameters. 167 of the 225 patients showed symptoms at the start of treatment.
Of these 167, 188 patients (70.7%) were symptom free at the end of the 3 year follow up.
Our figures show that EDTA treatment is a serious supplement or alternative to by pass surgery as well as balloon dilatation and medicinal treatment of calcification of the cardiac arteries.
Many other parameters were also reduced considerably. Our cautious conclusion to the study is that the risk of cardiac episodes or death (of all causes) is considerably reduced in patients with cardiovascular disease if they receive EDTA chelation in stead of or in addition to conventional treatment.
EDTA chelation is similarly well suited for secondary prevention in patients with cardiovascular disease. This means that EDTA treatment is especially well suited for prevention of cardiac episodes in patients with known heart disease.
Most of the patients who receive EDTA chelation can also expect an improvement in their quality of life.
This is nothing new for those of us who have worked with this treatment for the last 20 years.
But many people are unaware of EDTA’s existence.
With this study’s many clear conclusions, it is our hope that interest for this safe and effective treatment will increase.